New eczema cream shows promise in tiny trial
NCT ID NCT06923228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested a new ointment called CGB-500 (containing tofacitinib) against an approved cream (ruxolitinib) for atopic dermatitis, a type of eczema. Only 3 people aged 12 and older took part, applying both treatments to different skin areas twice daily for 4 weeks. The goal was to see if CGB-500 reduces eczema severity and is safe to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib ointment (CGB-500)
What this could lead to
If it works, this could point toward a new topical treatment option for atopic dermatitis that is as effective as existing creams.
What could go wrong
This is a very small early-phase trial with only 3 participants, so results may not apply to the broader population. The drug may not prove more effective than the comparator or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Dermatology Clinical Research
Fremont, California, 94538, United States